Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BrookDell Partners

Back

Private Equity

Andrea Alms Video:  Money In Motion 102 - Deep Dive Immunotherapy Cancer Market Part 3

April 2024 - Private Equity

posted by BrookDell Partners
1yr ago

TRANSCRIPT Hello, my name is Andrea Alms. I'm technology investor and financial manager and this is your money in motion. On the last episode, we unveiled fifth and fourth biggest immuno therapy companies in the world. On this episode, we unveiled the top three. Let's review. The immunotherapy market size is 131.8 billion, with a 12.1% growth rate, and the category the largest market size US dollar amount. First place goes to whom you know therapy at again $131.8 billion market size and a distant second place is chemotherapy, bone marrow transplant, antigen, drug conjugate and radiation therapy. Review by market size. Immunotherapy drug market is segmented into monoclonal antibodies, immunomodulators, vaccine, and others is estimated. Monoclonal antibodies are about 42% of the immunotherapy drug market. Third place goes to Abbvie. Abbvie. The NYSE ticker is ABBV. It is a Chicago, Illinois based global pharmaceutical company. AbbVie's key immuno therapy drug is Imbruvica, which is a Buton tyrosine kinase inhibitor. It has been approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Walden strong macro global bulimia as of April 1st, 2024, market cap 317.92 billion. As of year in 2023. Diluted earnings per share that's EPS trailing 12 months. TTM is $2.72. Revenue $54.50 $4.32 billion. Second place Merck is traded on the NYSE with the ticker of MRK. It is a Rahway, new Jersey based pharmaceutical company. The company's immunotherapy program is focused on the creation of checkpoint inhibitors and other types of immunotherapies. As of April 1st, 2023, market cap was 33 1.75 billion. As of year end 2023 EPS $0.14 revenue $60.12 billion. First place JNJ Johnson Johnson is traded on the NYSE. It is New Brunswick, new Jersey global pharmaceutical company. The company's key checkpoint inhibitor is called C T-cell, which is a Car T-cell therapy created for the treatment of multiple myeloma as of April 1st, 2024, market cap 380.22 billion. Year end 2023 EPS $5.21. Revenue 85.16 billion. Thank you. This is your money. Your money. in motion.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.